Company intelligence / Profile preview

Senhwa Biosciences, Inc.

New Taipei City, New Taipei City, Taiwan

Ownership: Public · 6492
Development stage: Phase 2

Overview

Recent positive clinical data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in Basal Cell Carcinoma showed three patients achieved partial response (PR) and ten had stable disease (SD). Two patients had progression-free survival exceeding 21 months. The drug demonstrated superior tolerability and disease control potential compared to current first- and second-line therapies.[2][8]

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

silmitasertib

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Senhwa Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senhwa Biosciences, Inc..

Explore the full profile